Needham Maintains Buy on Gilead Sciences, Raises Price Target to $200

Benzinga · 1d ago
Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $170 to $200.